This is the text extract for 2008-11-14 - Proposal relating to filgrastim, midazolam, mycophenolate mofetil and pegfilgrastim. Closes 4pm, Friday 28 November, browse documents here.

---

14 November 2008

Proposal relating to filgrastim, midazolam, mycophenolate mofetil and pegfilgrastim

PHARMAC and Roche Products (New Zealand) Limited have entered into an agreement relating to the supply of filgrastim (Neupogen) midazolam (Hypnovel), mycophenolate mofetil (Cellcept) and pegfilgrastim (Neulastim). In summary, the proposal would result in: § § § awarding Hospital Supply Status to the Neupogen brand of filgrastim; a reduction in the price and subsidy of midazolam injections; a reduction in the effective price and subsidy of mycophenolate mofetil through a rebate arrangement; a reduction in the effective price of pegfilgrastim through a discount on invoice; and subsidy and delisting protection being provided to the above products.

§ §

Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 4 pm on Friday, 28 November 2008 to: Andrew Davies Procurement Initiatives Manager PHARMAC PO Box 10 254 Wellington 6143 Email: andrew.davies@pharmac.govt.nz Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. Details of the proposal Filgrastim § A new 480 μg pre-filled syringe presentation of filgrastim would be listed as a Discretionary Community Supply pharmaceutical from 1 January 2009.

A244461 - T08-251 Page 1 of 2

---

§

Neupogen would become the Hospital Supply Status (HSS) brand of filgrastim in Section H of the Pharmaceutical Schedule from 1 April 2009, with a Discretionary Variance limit of 1%, until 31 December 2011. Neupogen would have protection from delisting until 31 December 2012.

§

Midazolam § The price and subsidy of the Hypnovel brand of midazolam injections would reduce from 1 January 2009 as follows (prices are ex-manufacturer and exclusive of GST):

Chemical Midazolam Midazolam Presentation Inj 1 mg per mL, 5 mL Inj 5 mg per mL, 3 mL Brand Hypnovel Hypnovel Pack size 10 5 Current price and subsidy $12.65 $14.00 Proposed price and subsidy $10.75 $11.90

§

Hypnovel would be protected from delisting and subsidy reduction until 30 June 2012. The Pfizer brand of midazolam would be reference priced to Hypnovel in Section B of the Pharmaceutical Schedule from 1 January 2009 as follows:

Chemical Midazolam Midazolam Presentation Inj 1 mg per mL, 5 mL Inj 5 mg per mL, 3 mL Brand Pfizer Pfizer Pack size 10 5 Current price $14.73 $19.64 Current subsidy $12.65 $14.00 Proposed subsidy $10.75 $11.90

§

Mycophenolate mofetil § The price and subsidy of Cellcept as listed in Section B of the Pharmaceutical Schedule would remain unchanged. Cellcept would be subject to an additional rebate on community subsidies, which would reduce its effective price and subsidy. Cellcept would be protected from delisting and subsidy reduction until 30 June 2012.

§

§

Pegfilgrastim § Neulastim would be listed in Section H of the Pharmaceutical Schedule from 1 January 2009 at $1395.00 per injection (ex-manufacturer, excluding GST). Neulastim would be subject to a discount on invoice to reduce its effective price to DHB hospitals. Neulastim would be protected from delisting until 31 December 2012.

§

§

A244461 - T08-251 Page 2 of 2